1. Scrip
  2. >>Business
  3. >>Deals

Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I

 
• By Jessica Merrill

Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.

Wooden little men holding hands on wooden boards background. Symbol of friendship, love and teamwork
Sanofi and Kymera partnered on a protein degrader for immunology and inflammation • Source: Shutterstock

Sanofi is partnering with Kymera Therapeutics, LLC. in a budding area of drug development – protein degradation – as it looks for new opportunities to expand in immunology and inflammation. The companies announced a collaboration on 9 July in which Sanofi agreed to pay Kymera $150m up front for rights to develop and commercialize first-in-class protein degrader therapies targeting interleukin-1 receptor associated kinase 4 (IRAK4) in patients with immune-inflammatory diseases and a second earlier-stage program.

In addition to the upfront payment, Sanofi also agreed to pay more than $2bn in potential development, regulatory and sales...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.